{"id":2555,"date":"2025-04-07T13:20:11","date_gmt":"2025-04-07T13:20:11","guid":{"rendered":"https:\/\/ashermantherapy.com\/?p=2555"},"modified":"2026-02-11T14:14:16","modified_gmt":"2026-02-11T14:14:16","slug":"asherman-syndrome-treatment-comparison-paula-vs-traditional-options","status":"publish","type":"post","link":"https:\/\/ashermantherapy-com.s54.somospecesvoladores.com\/index.php\/2025\/04\/07\/asherman-syndrome-treatment-comparison-paula-vs-traditional-options\/","title":{"rendered":"Asherman Syndrome Treatment Comparison: PAULA vs Traditional Options"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A new era in reproductive health<\/strong><\/p>\n

If you\u2019ve been diagnosed with Asherman Syndrome<\/strong> or struggle with thin endometrium<\/strong> and have experienced failed implantation<\/strong>, you know how emotionally and physically exhausting the search for effective treatment can be. For decades, traditional options have offered limited success. But now, an innovative therapy called PAULA<\/strong> is offering renewed hope to women worldwide.<\/p>\n

What is Asherman Syndrome and why is it so challenging?<\/strong><\/p>\n

Asherman Syndrome is an acquired uterine condition characterized by scar tissue<\/strong> formation inside the uterus, often caused by trauma after surgical procedures such as dilation and curettage (D&C). It affects up to 5% of infertile women<\/strong>, leading to missed periods, pain, and most critically recurrent implantation failure<\/strong>.<\/p>\n

Impact on Fertility<\/strong><\/p>\n

The scar tissue disrupts the normal architecture of the endometrial lining, impairing embryo implantation and increasing the risk of miscarriage. Similarly, a thin endometrium<\/strong>, defined as less than 5 mm, is another major barrier to successful pregnancy\u2014even with assisted reproductive technologies.<\/p>\n

Traditional treatments: limited but still necessary<\/strong><\/p>\n

Hysteroscopic adhesiolysis<\/span><\/p>\n

This surgical approach removes adhesions and is the first-line treatment<\/strong>. However, recurrence is common, especially in moderate to severe cases. Many women require multiple surgeries<\/strong>, and outcomes vary widely.<\/p>\n

Hormonal therapies<\/span><\/p>\n

Estrogen is often used post-surgery to stimulate endometrial regrowth. Yet, up to 30% of patients<\/strong> show poor response. Side effects and inconsistent results are common concerns.<\/p>\n

Mechanical barriers and PRP<\/span><\/p>\n

Other treatments include platelet-rich plasma (PRP)<\/strong>, intrauterine balloons<\/strong>, or hyaluronic acid gels<\/strong>\u2014used to support endometrial healing. These options provide modest improvements in endometrial thickness<\/strong> but lack long-term impact on live birth rates<\/strong>.<\/p>\n

Introducing PAULA: a regenerative breakthrough<\/strong><\/p>\n

What Is PAULA?<\/span><\/p>\n

PAULA (Patient-specific Autologous endometriaL Advanced therapy) is a stem cell-based regenerative treatment<\/strong> designed specifically for women with Asherman Syndrome<\/strong> and thin endometrium<\/strong>. Developed by leading experts in reproductive medicine, it uses CD133+ autologous bone marrow-derived stem cells<\/strong> to repair and regenerate the uterine lining.<\/p>\n

How PAULA Works<\/span><\/p>\n

    \n
  1. Mobilization<\/strong>: Stimulates the release of stem cells from the bone marrow.<\/li>\n
  2. Extraction (Apheresis)<\/strong>: Collects these stem cells from the bloodstream.<\/li>\n
  3. Processing<\/strong>: Isolates CD133+ cells in a GMP-certified lab.<\/li>\n
  4. Infusion<\/strong>: Delivers the stem cells directly to the uterus via a catheter.<\/li>\n
  5. Regeneration<\/strong>: The cells promote angiogenesis<\/strong> and tissue repair, improving endometrial receptivity.<\/li>\n<\/ol>\n

    Clinical evidence: What the research shows<\/strong><\/p>\n

    PAULA has been tested in a Phase I\/II clinical trial in Europe<\/strong>, showing:<\/p>\n